The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Poxviridae Infections Drug Market Research Report 2024
Synopsis
The global Poxviridae Infections Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Poxviridae Infections Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Poxviridae Infections Drug.
Report Scope
The Poxviridae Infections Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Poxviridae Infections Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Poxviridae Infections Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bavarian Nordic A/S
BioFactura, Inc.
CEL-SCI Corporation
Chimerix, Inc.
China Biologic Products, Inc.
CJ HealthCare Corp.
EpiVax, Inc.
N & N Pharmaceuticals Inc.
SIGA Technologies, Inc.
Takeda Pharmaceutical Company Limited
Tonix Pharmaceuticals Holding Corp.
Verrica Pharmaceuticals Inc.
Segment by Type
CJ-40011
24a
BA-368
Others
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Poxviridae Infections Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Poxviridae Infections Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Poxviridae Infections Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Poxviridae Infections Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Poxviridae Infections Drug.
Report Scope
The Poxviridae Infections Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Poxviridae Infections Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Poxviridae Infections Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bavarian Nordic A/S
BioFactura, Inc.
CEL-SCI Corporation
Chimerix, Inc.
China Biologic Products, Inc.
CJ HealthCare Corp.
EpiVax, Inc.
N & N Pharmaceuticals Inc.
SIGA Technologies, Inc.
Takeda Pharmaceutical Company Limited
Tonix Pharmaceuticals Holding Corp.
Verrica Pharmaceuticals Inc.
Segment by Type
CJ-40011
24a
BA-368
Others
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Poxviridae Infections Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Poxviridae Infections Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Poxviridae Infections Drug Market Overview
1.1 Product Overview and Scope of Poxviridae Infections Drug
1.2 Poxviridae Infections Drug Segment by Type
1.2.1 Global Poxviridae Infections Drug Market Value Comparison by Type (2024-2030)
1.2.2 CJ-40011
1.2.3 24a
1.2.4 BA-368
1.2.5 Others
1.3 Poxviridae Infections Drug Segment by Application
1.3.1 Global Poxviridae Infections Drug Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Poxviridae Infections Drug Market Size Estimates and Forecasts
1.4.1 Global Poxviridae Infections Drug Revenue 2019-2030
1.4.2 Global Poxviridae Infections Drug Sales 2019-2030
1.4.3 Global Poxviridae Infections Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Poxviridae Infections Drug Market Competition by Manufacturers
2.1 Global Poxviridae Infections Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Poxviridae Infections Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Poxviridae Infections Drug Average Price by Manufacturers (2019-2024)
2.4 Global Poxviridae Infections Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Poxviridae Infections Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Poxviridae Infections Drug, Product Type & Application
2.7 Poxviridae Infections Drug Market Competitive Situation and Trends
2.7.1 Poxviridae Infections Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Poxviridae Infections Drug Players Market Share by Revenue
2.7.3 Global Poxviridae Infections Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Poxviridae Infections Drug Retrospective Market Scenario by Region
3.1 Global Poxviridae Infections Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Poxviridae Infections Drug Global Poxviridae Infections Drug Sales by Region: 2019-2030
3.2.1 Global Poxviridae Infections Drug Sales by Region: 2019-2024
3.2.2 Global Poxviridae Infections Drug Sales by Region: 2025-2030
3.3 Global Poxviridae Infections Drug Global Poxviridae Infections Drug Revenue by Region: 2019-2030
3.3.1 Global Poxviridae Infections Drug Revenue by Region: 2019-2024
3.3.2 Global Poxviridae Infections Drug Revenue by Region: 2025-2030
3.4 North America Poxviridae Infections Drug Market Facts & Figures by Country
3.4.1 North America Poxviridae Infections Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Poxviridae Infections Drug Sales by Country (2019-2030)
3.4.3 North America Poxviridae Infections Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Poxviridae Infections Drug Market Facts & Figures by Country
3.5.1 Europe Poxviridae Infections Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Poxviridae Infections Drug Sales by Country (2019-2030)
3.5.3 Europe Poxviridae Infections Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Poxviridae Infections Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Poxviridae Infections Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Poxviridae Infections Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Poxviridae Infections Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Poxviridae Infections Drug Market Facts & Figures by Country
3.7.1 Latin America Poxviridae Infections Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Poxviridae Infections Drug Sales by Country (2019-2030)
3.7.3 Latin America Poxviridae Infections Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Poxviridae Infections Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Poxviridae Infections Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Poxviridae Infections Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Poxviridae Infections Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Poxviridae Infections Drug Sales by Type (2019-2030)
4.1.1 Global Poxviridae Infections Drug Sales by Type (2019-2024)
4.1.2 Global Poxviridae Infections Drug Sales by Type (2025-2030)
4.1.3 Global Poxviridae Infections Drug Sales Market Share by Type (2019-2030)
4.2 Global Poxviridae Infections Drug Revenue by Type (2019-2030)
4.2.1 Global Poxviridae Infections Drug Revenue by Type (2019-2024)
4.2.2 Global Poxviridae Infections Drug Revenue by Type (2025-2030)
4.2.3 Global Poxviridae Infections Drug Revenue Market Share by Type (2019-2030)
4.3 Global Poxviridae Infections Drug Price by Type (2019-2030)
5 Segment by Application
5.1 Global Poxviridae Infections Drug Sales by Application (2019-2030)
5.1.1 Global Poxviridae Infections Drug Sales by Application (2019-2024)
5.1.2 Global Poxviridae Infections Drug Sales by Application (2025-2030)
5.1.3 Global Poxviridae Infections Drug Sales Market Share by Application (2019-2030)
5.2 Global Poxviridae Infections Drug Revenue by Application (2019-2030)
5.2.1 Global Poxviridae Infections Drug Revenue by Application (2019-2024)
5.2.2 Global Poxviridae Infections Drug Revenue by Application (2025-2030)
5.2.3 Global Poxviridae Infections Drug Revenue Market Share by Application (2019-2030)
5.3 Global Poxviridae Infections Drug Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bavarian Nordic A/S
6.1.1 Bavarian Nordic A/S Corporation Information
6.1.2 Bavarian Nordic A/S Description and Business Overview
6.1.3 Bavarian Nordic A/S Poxviridae Infections Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bavarian Nordic A/S Poxviridae Infections Drug Product Portfolio
6.1.5 Bavarian Nordic A/S Recent Developments/Updates
6.2 BioFactura, Inc.
6.2.1 BioFactura, Inc. Corporation Information
6.2.2 BioFactura, Inc. Description and Business Overview
6.2.3 BioFactura, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 BioFactura, Inc. Poxviridae Infections Drug Product Portfolio
6.2.5 BioFactura, Inc. Recent Developments/Updates
6.3 CEL-SCI Corporation
6.3.1 CEL-SCI Corporation Corporation Information
6.3.2 CEL-SCI Corporation Description and Business Overview
6.3.3 CEL-SCI Corporation Poxviridae Infections Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 CEL-SCI Corporation Poxviridae Infections Drug Product Portfolio
6.3.5 CEL-SCI Corporation Recent Developments/Updates
6.4 Chimerix, Inc.
6.4.1 Chimerix, Inc. Corporation Information
6.4.2 Chimerix, Inc. Description and Business Overview
6.4.3 Chimerix, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Chimerix, Inc. Poxviridae Infections Drug Product Portfolio
6.4.5 Chimerix, Inc. Recent Developments/Updates
6.5 China Biologic Products, Inc.
6.5.1 China Biologic Products, Inc. Corporation Information
6.5.2 China Biologic Products, Inc. Description and Business Overview
6.5.3 China Biologic Products, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 China Biologic Products, Inc. Poxviridae Infections Drug Product Portfolio
6.5.5 China Biologic Products, Inc. Recent Developments/Updates
6.6 CJ HealthCare Corp.
6.6.1 CJ HealthCare Corp. Corporation Information
6.6.2 CJ HealthCare Corp. Description and Business Overview
6.6.3 CJ HealthCare Corp. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 CJ HealthCare Corp. Poxviridae Infections Drug Product Portfolio
6.6.5 CJ HealthCare Corp. Recent Developments/Updates
6.7 EpiVax, Inc.
6.6.1 EpiVax, Inc. Corporation Information
6.6.2 EpiVax, Inc. Description and Business Overview
6.6.3 EpiVax, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 EpiVax, Inc. Poxviridae Infections Drug Product Portfolio
6.7.5 EpiVax, Inc. Recent Developments/Updates
6.8 N & N Pharmaceuticals Inc.
6.8.1 N & N Pharmaceuticals Inc. Corporation Information
6.8.2 N & N Pharmaceuticals Inc. Description and Business Overview
6.8.3 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2019-2024)
6.8.4 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio
6.8.5 N & N Pharmaceuticals Inc. Recent Developments/Updates
6.9 SIGA Technologies, Inc.
6.9.1 SIGA Technologies, Inc. Corporation Information
6.9.2 SIGA Technologies, Inc. Description and Business Overview
6.9.3 SIGA Technologies, Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2019-2024)
6.9.4 SIGA Technologies, Inc. Poxviridae Infections Drug Product Portfolio
6.9.5 SIGA Technologies, Inc. Recent Developments/Updates
6.10 Takeda Pharmaceutical Company Limited
6.10.1 Takeda Pharmaceutical Company Limited Corporation Information
6.10.2 Takeda Pharmaceutical Company Limited Description and Business Overview
6.10.3 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product Portfolio
6.10.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
6.11 Tonix Pharmaceuticals Holding Corp.
6.11.1 Tonix Pharmaceuticals Holding Corp. Corporation Information
6.11.2 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Description and Business Overview
6.11.3 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product Portfolio
6.11.5 Tonix Pharmaceuticals Holding Corp. Recent Developments/Updates
6.12 Verrica Pharmaceuticals Inc.
6.12.1 Verrica Pharmaceuticals Inc. Corporation Information
6.12.2 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Description and Business Overview
6.12.3 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio
6.12.5 Verrica Pharmaceuticals Inc. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Poxviridae Infections Drug Industry Chain Analysis
7.2 Poxviridae Infections Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Poxviridae Infections Drug Production Mode & Process
7.4 Poxviridae Infections Drug Sales and Marketing
7.4.1 Poxviridae Infections Drug Sales Channels
7.4.2 Poxviridae Infections Drug Distributors
7.5 Poxviridae Infections Drug Customers
8 Poxviridae Infections Drug Market Dynamics
8.1 Poxviridae Infections Drug Industry Trends
8.2 Poxviridae Infections Drug Market Drivers
8.3 Poxviridae Infections Drug Market Challenges
8.4 Poxviridae Infections Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
